[조사자료] 글로벌 발기 부전 치료제 시장 (2023-2032) : 실데나필, 타다라필, 유데나필, 아바나필, 기타

■ 영문 제목 : Erectile Dysfunction Drugs Market By Products (Sildenafil, Tadalafil, Udenafil, Avanafil , Others), By Mode of Administration (Oral Medication , Injectable Medication ), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032
	■ 상품코드 : ALD23SEP102 ■ 조사/발행회사 : Allied Market Research ■ 발행일 : 2023년 4월 ■ 페이지수 : 417 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 ■ 조사대상 지역 : 세계

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User	USD5,730 ⇒환산￦7,735,500	견적의뢰/주문/질문
5 User	USD6,450 ⇒환산￦8,707,500	견적의뢰/주문/질문
Enterprise User	USD9,600 ⇒환산￦12,960,000	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

세계의 발기 부전 치료제 시장은 2022년 26억 달러 규모였으며 2023년부터 2032년까지 6.5%의 연평균 성장률로 성장하여 2032년에는 51억 달러에 이를 것으로 예상됩니다. 발기 부전(ED)은 모든 연령대의 남성에게 영향을 미치는 흔한 성 건강 질환입니다. 발기 부전은 성관계에 충분한 발기를 얻거나 유지할 수 없는 상태로 정의됩니다. 발기 부전(ED)은 고혈압, 당뇨병 또는 심장질환과 같은 기저 질환으로 인해 발생하는 경우가 많습니다. 발기 부전의 원인이 될 수 있는 다른 요인으로는 스트레스, 불안, 우울증, 신경 손상, 특정 약물, 흡연 및 음주와 같은 생활 습관 등이 있습니다. 발기 부전(ED)의 치료 옵션에는 약물, 생활 습관 변화 및 심리 상담이 포함됩니다.
발기 부전 치료제 시장의 성장을 이끄는 주요 요인은 당뇨병, 고혈압, 비만 등과 같은 만성 질환의 유병률이 증가하고 인도와 중국과 같은 개발도상국에서 발기 부전 치료와 관련된 이점에 대한 인식이 높아짐에 따라 시장의 성장을 촉진하고 있습니다. 또한 전 세계적으로 좌식 생활 방식의 채택이 증가하고 발기 부전 사례가 급증하면서 시장의 성장이 더욱 촉진되고 있습니다. 예를 들어, 2022년 미국 국립보건원에 따르면 발기 부전(ED)은 미국에서 흔한 질환으로, 매년 약 3천만 명의 미국 남성에게 영향을 미칩니다.
그러나 시야 흐림, 코막힘, 홍조 등 발기 부전 치료제와 관련된 부작용과 일반인의 발기 부전에 대한 인식 및 지식 부족은 향후 시장 성장을 저해할 것으로 예상됩니다. 반대로 발기 부전 치료에 대한 R&D 활동의 증가와 최신 제품 승인은 가까운 장래에 시장 성장을 위한 수익성 있는 기회를 제공할 것으로 예상됩니다.

발기 부전 치료제 시장은 제품, 투여 방식, 유통 채널 및 지역을 기준으로 세분화됩니다. 제품을 기준으로 시장은 실데나필 , 아반필, 타다라필, 유데나필 등으로 분류됩니다. 투여 방식에 따라 시장은 경구 약물과 주사 약물로 나뉩니다. 유통 채널에 따라 시장은 병원 약국, 소매 약국 및 온라인 약국으로 분류됩니다. 지역을 기준으로 시장은 북미 (미국, 캐나다 및 멕시코), 유럽 (독일, 프랑스, 영국, 이탈리아, 스페인 및 기타 유럽 지역), 아시아 태평양 (중국, 일본, 호주, 인도, 한국 및 기타 아시아 태평양) 및 중남미/중동/아프리카 (브라질, 남아프리카 공화국, 사우디 아라비아 및 기타 중남미/중동/아프리카)에서 분석됩니다.
이 보고서에서 프로파일링된 주요 기업은 Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sanofi, Inc, Sun Pharmaceutical Industries Ltd., Bayer AG, Vivus LLC., Adamed Pharma, Glenmark Pharmaceuticals Limited, and Cipla Ltd. 등이 있습니다.

이해 관계자를 위한 주요 이점
이 보고서는 2022년부터 2032년까지 발기 부전 치료제 시장 분석의 시장 부문, 현재 동향, 추정치 및 역학에 대한 정량적 분석을 제공하여 일반적인 발기 부전 치료제 시장 기회를 식별합니다.
시장 조사는 주요 동인, 제약 및 기회와 관련된 정보와 함께 제공됩니다.
포터의 다섯 가지 경쟁 요인 분석은 이해 관계자가 이익 지향적인 비즈니스 결정을 내리고 공급자-구매자 네트워크를 강화할 수 있도록 구매자와 공급자의 힘을 강조합니다.
발기 부전 치료제 시장 세분화에 대한 심층 분석은 일반적인 시장 기회를 결정하는 데 도움이 됩니다.
각 지역의 주요 국가는 글로벌 시장에 대한 매출 기여도에 따라 매핑됩니다.
시장 플레이어 포지셔닝은 벤치마킹을 용이하게하고 시장 플레이어의 현재 위치에 대한 명확한 이해를 제공합니다.
이 보고서에는 지역 및 글로벌 발기 부전 치료제 시장 동향, 주요 업체, 시장 부문, 응용 분야 및 시장 성장 전략에 대한 분석이 포함되어 있습니다.

주요 시장 부문
제품별
실데나필
타다라필
우데나필
아바나필
기타

투여 방식별
경구용 약물
주사제

유통 채널별
병원 약국
소매 약국
온라인 약국

지역별
북미
미국
캐나다
멕시코
유럽
독일
프랑스
영국
이탈리아
스페인
기타 유럽 지역
아시아 태평양
일본
중국
인도
호주
한국
기타 아시아 태평양 지역
중남미/중동/아프리카
브라질
사우디 아라비아
남아프리카 공화국
기타 중동 및 아프리카 지역

주요 기업
○ Adamed
○ Bayer AG
○ Cipla Ltd
○ Eli Lilly and Company
○ Glenmark Pharmaceuticals Limited
○ Pfizer Inc.
○ Sanofi
○ Sun Pharmaceutical Industries Limited
○ Teva Pharmaceutical Industries Ltd.
○ Vivus LLC.

■ 보고서 개요

CHAPTER 1 : 소개
CHAPTER 2 : 개요
CHAPTER 3 : 시장 동향
CHAPTER 4 : 발기 부전 치료제 시장, 제품별
CHAPTER 5 : 발기 부전 치료제 시장, 투여 방법별
CHAPTER 6 : 발기 부전 치료제 시장, 유통 채널별
CHAPTER 7 : 발기 부전 치료제 시장, 지역별
CHAPTER 8 : 경쟁 현황
CHAPTER 9 : 기업 정보

■ 보고서 목차

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of erectile dysfunction
3.4.1.2. Rise in the prevalence of psychological disorders

3.4.2. Restraints
3.4.2.1. Side effects associated with erectile dysfunction drugs

3.4.3. Opportunities
3.4.3.1. High growth potential in developing economies

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS
4.1. Overview
4.1.1. Market size and forecast
4.2. Sildenafil
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Tadalafil
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Udenafil
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Avanafil
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral Medication
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Injectable Medication
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacy
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Retail Pharmacy
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Pharmacy
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: ERECTILE DYSFUNCTION DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Products
7.2.3. Market size and forecast, by Mode of Administration
7.2.4. Market size and forecast, by Distribution Channels
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Products
7.2.5.1.3. Market size and forecast, by Mode of Administration
7.2.5.1.4. Market size and forecast, by Distribution Channels
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Products
7.2.5.2.3. Market size and forecast, by Mode of Administration
7.2.5.2.4. Market size and forecast, by Distribution Channels
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Products
7.2.5.3.3. Market size and forecast, by Mode of Administration
7.2.5.3.4. Market size and forecast, by Distribution Channels
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Products
7.3.3. Market size and forecast, by Mode of Administration
7.3.4. Market size and forecast, by Distribution Channels
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Products
7.3.5.1.3. Market size and forecast, by Mode of Administration
7.3.5.1.4. Market size and forecast, by Distribution Channels
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Products
7.3.5.2.3. Market size and forecast, by Mode of Administration
7.3.5.2.4. Market size and forecast, by Distribution Channels
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Products
7.3.5.3.3. Market size and forecast, by Mode of Administration
7.3.5.3.4. Market size and forecast, by Distribution Channels
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Products
7.3.5.4.3. Market size and forecast, by Mode of Administration
7.3.5.4.4. Market size and forecast, by Distribution Channels
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Products
7.3.5.5.3. Market size and forecast, by Mode of Administration
7.3.5.5.4. Market size and forecast, by Distribution Channels
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Products
7.3.5.6.3. Market size and forecast, by Mode of Administration
7.3.5.6.4. Market size and forecast, by Distribution Channels
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Products
7.4.3. Market size and forecast, by Mode of Administration
7.4.4. Market size and forecast, by Distribution Channels
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Products
7.4.5.1.3. Market size and forecast, by Mode of Administration
7.4.5.1.4. Market size and forecast, by Distribution Channels
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Products
7.4.5.2.3. Market size and forecast, by Mode of Administration
7.4.5.2.4. Market size and forecast, by Distribution Channels
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Products
7.4.5.3.3. Market size and forecast, by Mode of Administration
7.4.5.3.4. Market size and forecast, by Distribution Channels
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Products
7.4.5.4.3. Market size and forecast, by Mode of Administration
7.4.5.4.4. Market size and forecast, by Distribution Channels
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Products
7.4.5.5.3. Market size and forecast, by Mode of Administration
7.4.5.5.4. Market size and forecast, by Distribution Channels
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Products
7.4.5.6.3. Market size and forecast, by Mode of Administration
7.4.5.6.4. Market size and forecast, by Distribution Channels
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Products
7.5.3. Market size and forecast, by Mode of Administration
7.5.4. Market size and forecast, by Distribution Channels
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Products
7.5.5.1.3. Market size and forecast, by Mode of Administration
7.5.5.1.4. Market size and forecast, by Distribution Channels
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Products
7.5.5.2.3. Market size and forecast, by Mode of Administration
7.5.5.2.4. Market size and forecast, by Distribution Channels
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Products
7.5.5.3.3. Market size and forecast, by Mode of Administration
7.5.5.3.4. Market size and forecast, by Distribution Channels
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Products
7.5.5.4.3. Market size and forecast, by Mode of Administration
7.5.5.4.4. Market size and forecast, by Distribution Channels
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Pfizer Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Eli Lilly and Company
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Teva Pharmaceutical Industries Ltd.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Sanofi
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Bayer AG
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Vivus LLC.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.7. Adamed
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.8. Glenmark Pharmaceuticals Limited
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Cipla Ltd
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Sun Pharmaceutical Industries Limited
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 02. ERECTILE DYSFUNCTION DRUGS MARKET FOR SILDENAFIL, BY REGION, 2022-2032 ($MILLION)
TABLE 03. ERECTILE DYSFUNCTION DRUGS MARKET FOR TADALAFIL, BY REGION, 2022-2032 ($MILLION)
TABLE 04. ERECTILE DYSFUNCTION DRUGS MARKET FOR UDENAFIL, BY REGION, 2022-2032 ($MILLION)
TABLE 05. ERECTILE DYSFUNCTION DRUGS MARKET FOR AVANAFIL , BY REGION, 2022-2032 ($MILLION)
TABLE 06. ERECTILE DYSFUNCTION DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 08. ERECTILE DYSFUNCTION DRUGS MARKET FOR ORAL MEDICATION , BY REGION, 2022-2032 ($MILLION)
TABLE 09. ERECTILE DYSFUNCTION DRUGS MARKET FOR INJECTABLE MEDICATION , BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 11. ERECTILE DYSFUNCTION DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 12. ERECTILE DYSFUNCTION DRUGS MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 13. ERECTILE DYSFUNCTION DRUGS MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 14. ERECTILE DYSFUNCTION DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 19. U.S. ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 20. U.S. ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 21. U.S. ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 22. CANADA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 23. CANADA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 24. CANADA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 25. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 26. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 27. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 28. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 29. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 30. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 31. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 32. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 33. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 34. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 35. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 36. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 37. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 38. UK ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 39. UK ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 40. UK ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 41. ITALY ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 42. ITALY ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 43. ITALY ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 44. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 45. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 46. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 54. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 55. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 56. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 57. CHINA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 58. CHINA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 59. CHINA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 60. INDIA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 61. INDIA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 62. INDIA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 72. LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 73. LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 74. LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 75. LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 76. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 77. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 78. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 81. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 84. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 87. REST OF LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 88. PFIZER INC.: KEY EXECUTIVES
TABLE 89. PFIZER INC.: COMPANY SNAPSHOT
TABLE 90. PFIZER INC.: PRODUCT SEGMENTS
TABLE 91. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 92. PFIZER INC.: KEY STRATERGIES
TABLE 93. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 94. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 95. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 96. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 97. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 98. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 99. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 100. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 101. SANOFI: KEY EXECUTIVES
TABLE 102. SANOFI: COMPANY SNAPSHOT
TABLE 103. SANOFI: PRODUCT SEGMENTS
TABLE 104. SANOFI: PRODUCT PORTFOLIO
TABLE 105. BAYER AG: KEY EXECUTIVES
TABLE 106. BAYER AG: COMPANY SNAPSHOT
TABLE 107. BAYER AG: PRODUCT SEGMENTS
TABLE 108. BAYER AG: PRODUCT PORTFOLIO
TABLE 109. VIVUS LLC.: KEY EXECUTIVES
TABLE 110. VIVUS LLC.: COMPANY SNAPSHOT
TABLE 111. VIVUS LLC.: PRODUCT SEGMENTS
TABLE 112. VIVUS LLC.: SERVICE SEGMENTS
TABLE 113. VIVUS LLC.: PRODUCT PORTFOLIO
TABLE 114. ADAMED: KEY EXECUTIVES
TABLE 115. ADAMED: COMPANY SNAPSHOT
TABLE 116. ADAMED: PRODUCT SEGMENTS
TABLE 117. ADAMED: PRODUCT PORTFOLIO
TABLE 118. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES
TABLE 119. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
TABLE 120. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
TABLE 121. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
TABLE 122. GLENMARK PHARMACEUTICALS LIMITED: KEY STRATERGIES
TABLE 123. CIPLA LTD: KEY EXECUTIVES
TABLE 124. CIPLA LTD: COMPANY SNAPSHOT
TABLE 125. CIPLA LTD: PRODUCT SEGMENTS
TABLE 126. CIPLA LTD: PRODUCT PORTFOLIO
TABLE 127. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 128. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 129. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 130. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

※본 조사보고서 [글로벌 발기 부전 치료제 시장 (2023-2032) : 실데나필, 타다라필, 유데나필, 아바나필, 기타] (코드 : ALD23SEP102) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [글로벌 발기 부전 치료제 시장 (2023-2032) : 실데나필, 타다라필, 유데나필, 아바나필, 기타] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

글로벌 제네릭 의약품 시장 (2023-2032) : 심혈관, 감염, 암, 당뇨병, 기타
ALD23SEP154 / Allied Market Research / 2023년 6월 / 글로벌 제네릭 의약품 시장은 2022년에 385,320,00백만 달러로 평가되었으며 2032년에는 835,706,50백만 달러에 달할 것으로 예상되며, 2023년부터 2032년까지 8.1%의 연평균 성장률을 보일 것으로 전망됩니다.제네릭 의약품은 용량 형태, 효능, 투여 방식, 품질, 성능...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 제네릭 의약품 시장, 치료 용도별 CHAPTER 5 : 제네릭 의약품 시장, 투여 경로별 CHAPTER 6 : 제네릭 의약품 시장, 유통 채널별 CHAPTER 7 : 제네릭 의약품 시장, 지역별 CHAPTER 8 : 경쟁 현황 CHAPTER...

글로벌 의약품 약물 전달 시장 (2023-2032) : 경구 약물 전달, 비강 약물 전달, 안구 약물 전달, 국소 약물 전달, 기타
ALD23SEP156 / Allied Market Research / 2023년 6월 / 글로벌 의약품 약물 전달 시장은 2022년에 14억 9,872만 달러로 평가되었으며 2023년부터 2032년까지 4.4%의 연평균 성장률을 보이며 2032년에는 2조 3,727억 달러에 달할 것으로 예상됩니다. 약물 전달은 원하는 치료 효과를 얻기 위해...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 의약품 약물 전달 시장, 투여 경로별 CHAPTER 5 : 의약품 약물 전달 시장, 용도별 CHAPTER 6 : 의약품 약물 전달 시장, 지역별 CHAPTER 7 : 경쟁 현황 CHAPTER 8 : 기업 정보...

글로벌 죽상동맥경화증 치료제 시장 (2023-2032) : 항혈소판제 및 항응고제, 콜레스테롤 저하제, ACE 억제제, 기타
ALD23SEP122 / Allied Market Research / 2023년 4월 / 글로벌 죽상동맥경화증 치료제 시장은 2022년 20,608.51백만 달러에 달했으며 2032년에는 27,711.92백만 달러에 달할 것으로 예상되며, 2023년부터 2032년까지 3%의 연평균 성장률을 보일 것으로 전망됩니다. 죽상동맥경화증은 플라크가 쌓여 동맥 벽이 딱딱해져 정맥이 좁아지는...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 죽상동맥경화증 치료제 시장, 약제 유형별 CHAPTER 5 : 죽상동맥경화증 치료제 시장, 투여 경로별 CHAPTER 6 : 죽상동맥경화증 치료제 시장, 유통채널별 CHAPTER 7 : 죽상동맥경화증 치료제 시장, 지역별 CHAPTER 8 : 경쟁 현황 CHAPTER 9...

글로벌 림프종 치료제 시장 (2023-2032) : 호지킨 림프종, 비호지킨 림프종
ALD23SEP105 / Allied Market Research / 2023년 4월 / 세계의 림프종 치료제 시장은 2022년 156억 9,145만 달러로 평가되며 2023년부터 2032년까지 8.4%의 연평균 성장률을 보이며 2032년에는 352억 7,450만 달러에 달할 것으로 예상됩니다. 림프종은 감염 및 기타 질병과 싸우는 데 도움이...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 림프종 치료제 시장, 질병 유형별 CHAPTER 5 : 림프종 치료제 시장, 치료 유형별 CHAPTER 6 : 림프종 치료제 시장, 투여 경로별 CHAPTER 7 : 림프종 치료제 시장, 유통 채널별 CHAPTER 8 : 림프종 치료제...

글로벌 근골격계 질환 (MSD) 치료제 시장 (2023-2032) : 진통제, DMARD, 코르티코 스테로이드, 기타
ALD23SEP123 / Allied Market Research / 2023년 4월 / 글로벌 근골격계 질환 (MSD) 치료제 시장은 2022년 834억 7,424만 달러 규모였으며 2023년부터 2032년까지 4.2%의 연평균 성장률을 보이며 2032년에는 126억 3,022만 달러에 달할 것으로 예상됩니다. 근골격계 질환(MSD)은 근육, 뼈, 관절에 영향을...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 근골격계 질환(MSD) 치료제 시장, 약품 유형별 CHAPTER 5 : 근골격계 질환(MSD) 치료제 시장, 투여 경로별 CHAPTER 6 : 근골격계 질환(MSD) 치료제 시장, 유통 채널별 CHAPTER 7 : 근골격계 질환(MSD) 치료제 시장, 지역별 CHAPTER 8...